Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation of potential power of F-THK5351 detecting astrogliosis as a marker of neurodgeneration

Trial Profile

Evaluation of potential power of F-THK5351 detecting astrogliosis as a marker of neurodgeneration

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Oct 2018

At a glance

  • Drugs Fluorine 18 THK 5351 (Primary)
  • Indications Corticobasal degeneration; Dementia; Neurodegenerative disorders; Progressive supranuclear palsy
  • Focus Diagnostic use
  • Most Recent Events

    • 03 Oct 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top